Verantos and Lundbeck Partner for Migraine Care Implementing Advanced Real-World Evidence

Verantos, the market leader in high-validity real-world evidence (RWE) generation, announced a partnership with Lundbeck, a global biopharmaceutical company specializing in brain diseases. Together, the two companies will collaborate on a study to enable real-world evidence in support of migraine therapy.

Real-world evidence is clinical evidence, obtained outside the context of randomized controlled trials, regarding the use, benefits and risks of a medical product.

Traditionally, migraine has been difficult to study and treat using real-world data because patient characteristics and outcomes are difficult to identify accurately. Advanced real-world evidence uses AI-powered deep phenotyping and linked outcomes to understand disease progression and treatment effectiveness. 

"We are delighted to collaborate with Lundbeck in their advanced RWE program," said Dan Riskin, MD, CEO of Verantos. "Using routinely collected data to enable tailored therapy pushes the boundaries of neuroscience and demonstrates Lundbeck's commitment to innovation and patient-centricity."

"Through our multiple studies with Verantos, we have appreciated the firm's scientific rigor and consistent delivery," said Steve Kymes, Director, Health Economics and Outcomes Research at Lundbeck. "Our ongoing partnership enables us to better understand our patient population, improve our offerings, and ultimately benefit the patients who suffer from migraine and the providers who care for these patients."